Prostate cancer survivors benefit from non-vigorous activity, walking

the ONA take:

After prostate cancer diagnosis, at least five hours of non-vigorous activity or 3 hours of walking is positively associated with better hormone and vitality functioning, according to a study published in the Journal of Cancer Survivorship.

Siobhan Phillips, PhD, MPH, at Northwestern University Feinberg School of Medicine and fellow researchers prospectively examined 1,917 men diagnosed with non-metastatic prostate cancer in the Health Professionals Follow-Up Study.

They looked at associations between activity and sedentary behavior after prostate cancer diagnosis in terms of health-related quality of life.

The researchers found that, upon adjusting for confounders, higher duration of non-vigorous and walking activity were associated with higher vitality and hormonal functioning scores.

The effects approached clinical significance for men in the highest versus lowest categories, with survivors who walked at least 90 minutes a week at a normal or faster pace reporting higher scores than men who walked less than 90 minutes a week at an easy pace.

Total activity was found to be associated with higher hormone and vitality functioning in men who were at least five years post-treatment and had more advanced disease.

“Encouraging men to engage in non-vigorous activity and walking may be helpful for managing prostate cancer-related health-related quality of life,” the authors concluded.

Why exercise improves prostate cancer outcomes
After prostate cancer diagnosis, at least five hours of non-vigorous activity or 3 hours of walking is beneficial.
Many prostate cancer survivors experience compromised health-related quality of life ( HRQOL) as a result of prostate cancer. We examined relationships between types and intensities of activity and sedentary behavior and prostate cancer-related HRQOL, overall, and by demographic, disease, and treatment characteristics.
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs